Company launches 1964 Supply Co.™ medical cannabis products in the U.K. through a distribution partnership with 4C LABS VANCOUVER, British Columbia, April 12, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products is pleased to announce the entry of its award-winning 1964 Supply Co.™ brand into the UK medical cannabis market through a distribution partnership with 4C LABS. The partnership establishes the first international route‑to‑market for 1964 Supply Co.™’s medical cannabis products, building on successful wholesale exports in 2025, and expands the total addressable market for Canada’s top premium brand. “The U.K. is a rapidly...

NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive US$22.5 million in milestone payments from NeurocrineTokyo, Japan and Cambridge, UK, 13 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated and dosed the first patient(s) in a Phase 2 clinical study of NBI-1117570 (“NBI-’570”) in adults with schizophrenia. As a result, Nxera will receive milestone payments of US$22.5 million from Neurocrine pursuant to the agreement. The milestone payments will be recognised as revenue in Q1 FY2026. NBI-‘570 is an investigational, orally administered, dual muscarinic M1/M4 receptor...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer, an area of high unmet medical need Data demonstrated clinically meaningful antitumor activity across all HER2 expression levels and a manageable safety profile, with centrallyi HER2-tested patients showing a confirmed objective response rate of 47.9% in all evaluable patients, 49.3% in patients with prior immune checkpoint inhibitor treatment, and a median progression-free survival of 8.1 months Largest trial to date to report results for a HER2-targeted antibody-drug conjugate in this indication supports potential of trastuzumab pamirtecan in real-world patient populations, including patients with lower HER2 expression...

VANCOUVER, BC, April 10, 2026 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: DGTEF) (FSE: 9880) (“DATT” or the “Company”), a technology focused investment issuer, announces that, in connection with a continuous disclosure review by the British Columbia Securities Commission (the “BCSC”), the Company intends to amend and refile certain previously filed financial statements and related management’s discussion and analysis (“MD&A”). The Company has determined that its previously filed:audited annual financial statements and MD&A for the year ended July 31, 2025; and  interim financial statements and MD&A for subsequent periods contain disclosure and accounting errors relating primarily to:the accounting treatment and valuation of the Company’s acquisition of LiquidLink AI Corp.;  the accounting...

VANCOUVER, BC, April 10, 2026 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: DGTEF) (FSE: 988) (“DATT” or the “Company”), a technology focused investment issuer, is issuing this news release at the request of the British Columbia Securities Commission (the “BCSC”) to provide supplemental, corrective and clarifying information regarding its news releases dated June 30, 2025 and May 7, 2025, including its material change report dated May 7, 2025 (collectively, the “Prior Disclosure”). Retraction of Prior Disclosure The Company retracts certain disclosure in the Prior Disclosure relating to the LiquidLink AI Corp. business. The retracted disclosure includes statements regarding:The acquisition enables the company to acquire Ripple (XRP) and LiquidLink is developing Xrpfy that enables users to search for tokenized...

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Sandisk Corporation (Nasdaq: SNDK) will become a component of the Nasdaq-100 Index® (NDX®) replacing Atlassian Corporation (Nasdaq: TEAM) prior to market open on Monday, April 20, 2026. These updates are consistent with the current Nasdaq-100 Index® methodology, in effect through April 30, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world’s leading index providers, offering a comprehensive suite of rules-based benchmarks and indexes. The Nasdaq-100 Index® — which measures the performance of 100 of the largest Nasdaq-listed non-financial companies — is tracked by more than 200 investment...

GREELEY, Colorado, April 10, 2026 (GLOBE NEWSWIRE) — Pilgrim’s Pride Corporation (NASDAQ: PPC) (the “Company”) announced today the early tender results for its cash tender offer (the “Tender Offer”) for up to $250 million aggregate principal amount (the “Maximum Tender Amount”) of its 6.250% Senior Notes due 2033 (the “Notes”). The Company has been advised that as of 5:00 p.m., New York City time, on April 10, 2026 (such date and time, the “Early Tender Date”), $471,546,000 aggregate principal amount of Notes had been validly tendered and not validly withdrawn in the Tender Offer. Withdrawal rights for the Notes expired on the Early Tender Date. The Tender Offer is being made upon the terms, and subject to the conditions, previously described in the offer to purchase dated March 30, 2026 (the “Offer to Purchase”). The Company refers...

MIAMI, April 10, 2026 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, announces the initial closing of the transfer of its Virginia operations into Arboretum Virginia LLC, a wholly-owned subsidiary of Arboretum Bidco LLC (“Arboretum”), and the closing and initial funding of its new money exit facility (the “Exit Facility”) with Arboretum, in connection with the Company’s previously announced restructuring transactions (the “Restructuring Transactions”). Arboretum, which intends to operate under the trade name “Ayr Wellness,” is the entity established by the Company’s senior secured noteholders as the designated purchaser under the Master Purchase Agreement, dated November 14, 2025 (the “MPA”). Additional state-level operations...

Not for distribution to United States Newswire Services or for dissemination in the United States VANCOUVER, British Columbia, April 10, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX- V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce that it has closed a non-brokered private placement offering of 1,110,000 national flow-through shares in the capital of Brixton (“FT Shares”) at a price of $1.35 per FT Share and 1,771,111 critical mineral flow-through shares in the capital of Brixton (the “CMFT Shares”) at a price of $1.44 per CMFT Share, for combined gross proceeds of $4,048,899.84 (the “Offering”). The gross proceeds from the sale of FT Shares will be used to incur “Canadian exploration expenses” and “flow-through mining expenditures” as defined in the Income Tax Act (Canada) (the “Act”). The gross...